E.D. Kreuser - Concepedia

Author

E.D. Kreuser

Also Known As

E D Kreuser, E Kreuser, E-D Kreuser, E. -D. Kreuser, E. D. KREUSER, E. D. Kreuser, E. Kreuser, E.-D. Kreuser, E.D Kreuser, E.D. KREUSER

130

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Freie Universität Berlin Krankenhaus Barmherzige Brüder Humboldt-Universität zu Berlin Medizinische Hochschule Hannover University Hospital Heidelberg

About

E.D. Kreuser is an author at Freie Universität Berlin specializing in medicine, immunology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	993
2	Health Sciences	3	3	492
3	Cell Biology	3	3	92
4	Public Health	1	1	64
5	Gastroenterology	1	1	38

E.D. Kreuser

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases Jean‐Jacques Body, Ingo Diel, E.D. Kreuser, Annals of Oncology Bone DiseaseBone HealthSkeletal ComplicationsOrthopaedic SurgeryHealth Sciences	2003	414
Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer Ingo Diel, Jean‐Jacques Body, E.D. Kreuser, European Journal of Cancer Bone DiseaseBone HealthOncologyLong-term TreatmentBisphosphonate Ibandronate	2004	164
Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. Wolfgang Hiddemann, Michael Unterhalt, Richard Herrmann, Journal of Clinical Oncology	1998	113
Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma H.J. Weh, H. Wilke, Judith Dierlamm, Annals of Oncology Pretreated PatientsSurgical OncologyWeekly TherapyMedicinePharmacology	1994	76
A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group D. Peest, H. Deicher, R. Coldewey, European Journal of Cancer Hematological MalignancyMedicineImmunologyHematologyMyeloid Neoplasia	1995	73
Reproductive Toxicity with and without LHRH<sub>A</sub>Administration During Adjuvant Chemotherapy in Patients with Germ Cell Tumors E.D. Kreuser, W. D. Hetzel, Richard E. Hautmann, Hormone and Metabolic Research SpermatogenesisFertilityReproductive ToxicityReproductive HealthAdjuvant Chemotherapy	1990	64
Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group. Michael Unterhalt, Richard Herrmann, Markus Tiemann, PubMed	1996	59
Recombinant human stem cell factor stimulates growth of a human glioblastoma cell line expressing c-kit protooncogene. W. E. Berdel, Sven de Vos, J. Mäurer, PubMed ImmunologyCell ProliferationStem Cell BiologyGliomaTumor Biology	1992	50
Adhesion receptors in malignant transformation and dissemination of gastrointestinal tumors Michael Streit, R Schmidt, R. U. Hilgenfeld, Journal of Molecular Medicine Gastrointestinal OncologyCell AdhesionAdhesion ReceptorsGastroenterologyColorectal Cancer	1996	38
Synergistic antitumor interactions between newly synthesized ruthenium complexes and cytokines in human colon carcinoma cell lines. E.D. Kreuser, Bernhard K. Keppler, W. E. Berdel, PubMed	1992	34

Page 1